The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

9 More presentations in this session

Presentation thumbnail

Discussant review - EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mo

Professor L. Kober (Copenhagen, DK)

Presentation thumbnail

Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure: first data from the TITRATE-HF study

Professor J. Brugts (Rotterdam, NL)

Presentation thumbnail

Discussant review - The TITRATE-HF study

Professor J. Ezekowitz (Edmonton, CA)

Presentation thumbnail

First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure

Doctor A. Spahillari (Durham, US)

Presentation thumbnail

Discussant review - TEAM-HF: Implementation Study of Accelerated Heart Failure Guideline-Directed Medical Therapy in a General Cardiology Clinic

Professor J. Celutkiene (Vilnius, LT)

Access the full session

Session thumbnail

Late breaking clinical trials: drugs and disease management

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Cardiorenal effects and safety of initiation of empagliflozin after acute myocardial infarction

Congress Presentation

Where do we stand with SGLT2i post-myocardial infarction?

Congress Presentation

Discussant review - EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mo

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources